Background
Abbott Laboratories held a patent on extended-release formulations of clarithromycin, the active ingredient in Biaxin® XL, a widely prescribed antibiotic. When Sandoz filed an ANDA to market generic clarithromycin ER and Abbott filed a Hatch-Waxman infringement suit, Abbott also moved for a preliminary injunction to prevent Sandoz from launching its generic product before the patent dispute was resolved.
Prior to the Supreme Court’s 2006 decision in eBay Inc. v. MercExchange, Federal Circuit precedent had held that a patentee who establishes a likelihood of success on validity and infringement is presumed to suffer irreparable harm — making preliminary injunctions nearly automatic in patent cases where the patentee could show a viable claim. The Supreme Court’s eBay decision rejected that automatic-presumption rule for permanent injunctions, holding that courts must apply the traditional four-factor equitable test. The question in Abbott v. Sandoz was whether eBay also eliminated the presumption of irreparable harm at the preliminary injunction stage.
The Court’s Holding
The Federal Circuit en banc held that yes, eBay’s reasoning applied to preliminary injunctions as well. A patent plaintiff seeking a preliminary injunction must demonstrate all four traditional factors: (1) likelihood of success on the merits; (2) likelihood of irreparable harm in the absence of an injunction; (3) that the balance of hardships tips in the plaintiff’s favor; and (4) that the public interest would not be disserved by an injunction. The presumption of irreparable harm no longer applied. Courts must independently assess whether the patentee has demonstrated actual irreparable harm — lost market share, price erosion, reputational damage, or other concrete harms that damages cannot adequately remedy — before granting preliminary relief.
Applied to the facts, the court found that the district court had relied on the old presumption framework and remanded for reconsideration under the corrected standard. The court acknowledged that entry of a generic competitor in pharmaceutical markets can constitute irreparable harm in many circumstances — due to the permanent nature of price erosion and market share loss — but that this must be demonstrated rather than presumed.
Key Takeaways
- eBay’s rejection of the automatic presumption of irreparable harm applies to preliminary injunctions in patent cases, not just permanent injunctions — patentees must demonstrate irreparable harm under the traditional four-factor equitable test.
- In Hatch-Waxman pharmaceutical cases, irreparable harm from generic entry can often be demonstrated through evidence of price erosion, market share loss, and damage to brand positioning — but these must be shown on the facts, not merely assumed.
- Generic drug companies gained significant litigation leverage from this ruling: the path to a preliminary injunction blocking generic launch became meaningfully harder for brand pharmaceutical companies.
- Courts must weigh all four preliminary injunction factors independently — a strong likelihood of success on the merits does not substitute for a showing of irreparable harm.
Why It Matters
Abbott v. Sandoz reshaped the preliminary injunction landscape in pharmaceutical patent litigation. Before eBay and Abbott, brand pharmaceutical companies could often block generic entry at the preliminary injunction stage by showing a colorable patent claim — the presumption of irreparable harm did most of the work. After Abbott, brands had to build a complete factual record showing that money damages would be inadequate and that permanent harm would result from generic entry pending trial.
The practical consequences were significant: generic drug companies gained the ability to launch product at risk with greater confidence that courts would not reflexively enjoin them. For brand companies, the decision made thorough preliminary injunction briefing — including expert evidence on market harm — essential to protecting patent exclusivity during Hatch-Waxman litigation. The case also contributed to broader uncertainty about the strength of pharmaceutical patent exclusivity, a topic of ongoing debate among policy makers, generic companies, and brand manufacturers.